Related Experiment Video
Updated: Aug 17, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment
Hui Quan1, Xiaohui Luo, Tom Capizzi
1Clinical Biostatistics and Research Decision Sciences, Merck Research Laboratories, RY34-A320, 126 E. Lincoln Ave., Rahway, NJ 07065-0914, USA. hui_quan@merck.com
Abstract:
Frequently, multiple doses of an active treatment and multiple endpoints are simultaneously considered in the designs of clinical trials. For these trials, traditional multiplicity adjustment procedures such as Bonferroni, Hochberg and Hommel procedures can be applied when treating the comparisons of different doses to the control on all endpoints at the same level. However, these approaches will not take into account the possible dose-response relationship on each endpoint, and therefore are less specific and may have lower power. To gain power, in this paper, we consider the problem as a two-dimensional multiplicity problem: one dimension concerns the multiple doses and the other dimension concerns the multiple endpoints. We propose procedures which consider the dose order to form the closure of the procedures and control the family-wise type I error rate in a strong sense. For this two-dimensional problem, numerical examples show that procedures proposed in this paper in general have higher power than the commonly used procedures (e.g. the regular Hochberg procedure) especially for comparing the higher dose to the control.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Regimen: Multiple Oral Dosage
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions